|
|
|
AREDS2 DNA Detail
|
|
|
| Records Return:
(296)
|
|
|
|
| dbGaP Submitter Subject ID (ID2) | Coriell Sample ID | Consent | Control | Gender | Race | Age | Baseline Max AMD Severity | Final Max AMD Severity |
| AR2_0258 | ED148218 | General Research Use | No | Male | White | 80 | 7 - AREDS AMD Severity Scale Step 7 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_0466 | ED148854 | General Research Use | No | Male | White | 82 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_0533 | ED148676 | General Research Use | No | Male | White | 84 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_1474 | ED148515 | General Research Use | No | Female | White | 81 | 7 - AREDS AMD Severity Scale Step 4 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_1791 | ED148572 | General Research Use | No | Male | White | 80 | 7 - AREDS AMD Severity Scale Step 7 | 8 - AREDS AMD Severity Scale Step 8 |
| AR2_2125 | ED149845 | General Research Use | No | Female | White | 83 | 10 - Central GA | 10 - Central GA |
| AR2_2485 | ED149941 | General Research Use | No | Female | White | 83 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_2700 | ED148732 | General Research Use | No | Male | White | 80 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_3389 | ED148194 | General Research Use | No | Male | White | 82 | 6 - AREDS AMD Severity Scale Step 5 | 11a - Neovascular AMD with definite presence of one of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_3785 | ED149026 | General Research Use | No | Female | White | 82 | 7 - AREDS AMD Severity Scale Step 6 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_3886 | ED149695 | General Research Use | No | Female | White | 80 | 5 - AREDS AMD Severity Scale Step 5 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_3965 | ED148406 | General Research Use | No | Female | White | 82 | 7 - AREDS AMD Severity Scale Step 6 | 9 - AREDS AMD Severity Scale Step 9 |
| AR2_4243 | ED149989 | Eye Disease Only | Yes | Female | White | 80 | | |
| AR2_0283 | ED148725 | General Research Use | No | Male | White | 83 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_0393 | ED148466 | General Research Use | No | Female | White | 83 | 7 - AREDS AMD Severity Scale Step 7 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_0493 | ED148689 | General Research Use | No | Female | White | 84 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_0637 | ED148695 | General Research Use | No | Female | White | 82 | 7 - AREDS AMD Severity Scale Step 7 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_0878 | ED149143 | General Research Use | No | Female | White | 83 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_0918 | ED149216 | General Research Use | No | Female | White | 80 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_0968 | ED149734 | General Research Use | No | Female | White | 80 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
|
|
|